MedCity News November 3, 2024
Archon Biosciences’ antibody cages change the structure of an antibody to control how a drug distributes in the body. The startup comes from the lab of David Baker, the University of Washington professor of biochemistry recently awarded the Nobel Prize in Chemistry for his work in computational protein design.
Over decades, antibodies have established themselves as a key therapeutic modality for a wide range of diseases. But antibodies as they are found in nature did not evolve to be used as drugs, says James Lazarovits, co-founder and CEO of Archon Biosciences. These proteins became drugs because scientists co-opted them to do things.
One of the limitations of currently available antibodies is the therapeutic window, which is the dose range within...
Today's Sponsors
Today's Sponsor